Abstract
We report a case of a 51-year-old man with esophageal cancer who had a complete pathological response to preoperative chemotherapy with a combination of docetaxel, cisplatin and 5-fluorouracil (DCF). Endoscopy and esophagography showed a type II tumor 8 cm in diameter, located in the upper thoracic esophagus. On computed tomography the diagnosis was T3N1M0, stage III disease according to TNM classification. Before surgery, the patient received DCF therapy, consisting of docetaxel (60 mg/m2) on day 1, cisplatin (60 mg/m2) on day 1, and 5-fluorouracil (800 mg/m2) on days 1–5. The patient had grade 3 hematological toxicity, but two courses were administered as scheduled. After chemotherapy, esophagography and computed tomography showed that the tumor had shrunk. Esophagectomy with three-field lymph node dissection was performed. Histopathologically, an ulcer scar was found, with no residual cancer cells. There were no metastases in dissected lymph nodes. This regimen is considered to have a high potential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.
Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, Nakamura T, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol (meeting abstracts). 2008;26(Suppl 15):4510.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–15.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–7.
Japanese Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition. Esophagus. 2004;61–88:107–25.
Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241: 810–7; discussion 817–20.
Ura T, Nagase M, Fujii H, Hironaka S, Hatooka S, Hosoya Y, et al. Feasibility study of preoperative docetaxel (D), cisplatin (C), and fluorouracil (F) in esophageal cancer. ASCO Gastrointestinal Cancers Symposium 2010, abstract 81.
Kato H. Lymph node dissection for thoracic esophageal carcinoma. Two- and 3-field lymph node dissection. Ann Chir Gynaecol. 1995;84(2):193–9.
Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K, Numasaki H, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2002. Esophagus. 2010;7:7–22.
Roth AD, Maibach R, Falk S, Stupp R, Saletti P, Kãberle D, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2004;22(Suppl 14):abstract 4020.
Katori H, Tsukuda M, Mochimatu I, Ishitoya J, Kawai S, Mikami Y, et al. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer. 2004;90(2):348.
Shimakawa T, Naritaka Y, Asaka S, Isohata N, Yamaguchi K, Murayama M, et al. A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy). Anticancer Res. 2010;30(1):221–6.
Watanabe M, Nagai Y, Iwagami S, Miyamoto Y, Hayashi N, Baba H, et al. Phase II study of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with node-positive esophageal cancer. J Clin Oncol. 2010;28(Suppl 15):abstract e14535.
Baba H, Nagai Y, Iwagami S, Miyamoto Y, Ikeda O, Hayashi N, et al. Efficacy and safety of induction chemotherapy with docetaxel/cisplatin/5-FU for patients with node-positive esophageal cancer. ASCO Gastrointestinal Cancers Symposium 2010, abstract 86.
Iwaya T, Kimura Y, Noda Y, Nishizuka S, Matsuo T, Ishida K, et al. Evaluation of primary chemotherapy with docetaxel, cisplatin, and fluorouracil for advanced esophageal squamous cell carcinoma. ASCO Gastrointestinal Cancers Symposium 2010, abstract 117.
Acknowledgments
We express special thanks to Professor Toshiro Niki for his great contribution to reviewing the pathological specimens.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ui, T., Nagase, M., Hosoya, Y. et al. A patient with esophageal squamous cell carcinoma who had a complete pathological response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. Esophagus 8, 59–62 (2011). https://doi.org/10.1007/s10388-011-0253-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10388-011-0253-0